Advertisement
Screener

EMERGENT BIOSOLUTIONS INC. (EBS) EBITDA

EMERGENT BIOSOLUTIONS INC. (EBS) EBITDA

  • 2026-06-30: Basis Reported; EBITDA -$101.10M*; Operating income -$125.10M; Depreciation and amortization $24.00M*.
  • 2026-03-31: Basis Reported; EBITDA $34M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA -$4.4M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA $99.90M*; Operating income $76.50M; Depreciation and amortization $23.40M*.

Complete source-backed ebitda history.

Available history
2009-12-31 to 2026-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported-$101.10M*-$125.10M$24.00M*$234.30M-43.15%*$2.10M*$56.10M*$97.10M$9.20M$44.60M$13.90M
2026-03-31Reported$34M(m)(m)(m)21.78%$2.40M-$33.80M$72.00M$10.50M$46.60M$6.60M
2025-12-31Reported-$4.4M(m)(m)(m)-2.96%(m)(m)(m)(m)(m)(m)
2025-09-30Reported$99.90M*$76.50M$23.40M*$231.10M43.23%*$3.40M*-$2.30M*$85.90M$13.50M$38.90M$6.40M
2025-06-30Reported$25.10M*$1.60M$23.50M*$140.90M17.81%*$2.90M*$106.40M*$66.90M$12.50M$43.70M-$4.80M
2025-03-31Reported$75.3M(m)(m)(m)33.89%$3.60M-$11.20M$88.50M$15.10M$52.40M$24.70M
2024-12-31Reported$16.5M(m)(m)(m)8.47%(m)(m)(m)(m)(m)(m)
2024-09-30Reported$90.90M*$64.50M$26.40M*$293.80M30.94%*$5.80M*$153.70M*$122.60M$13.80M$76.60M$27.60M
2024-06-30Reported-$175.00M*-$203.50M$28.50M*$254.70M-68.71%*$4.60M*$47.50M*$296.10M$32.70M$85.90M$13.30M
2024-03-31Reported$67.7M(m)(m)(m)22.54%$10.80M-$62.60M$144.60M$15.10M$84.70M$3.10M
2023-12-31Reported-$14.2M(m)(m)(m)-5.13%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$214.10M*-$242.10M$28.00M*(m)(m)$12.60M*$60.00M*$176.80M$15.30M$86.00M-$2.50M
2023-06-30Reported-$260.00M*-$292.90M$32.90M*(m)(m)$12.50M*-$114.40M*$190.60M$26.00M$91.40M$11.20M
2023-03-31Reported-$113M(m)(m)(m)-68.78%$15.10M-$184.00M$152.90M$40.70M$101.30M$25.60M
2022-12-31Reported-$19.6M(m)(m)(m)-5.94%(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$13.10M*-$45.30M$32.20M*(m)(m)$27.90M*-$74.00M*$147.20M$42.20M$81.80M$19.90M
2022-06-30Reported-$31.80M*-$76.30M$44.50M*(m)(m)$32.10M*-$15.60M*$169.80M$49.80M$81.10M-$26.40M
2022-03-31Reported$37.8M(m)(m)(m)12.40%$32.20M-$37.30M$155.90M$46.40M$84.80M-$100.00K
2021-12-31Reported$295.4M(m)(m)(m)41.95%(m)(m)(m)(m)(m)(m)
2021-09-30Reported-$12.00M*-$44.70M$32.70M*(m)(m)$55.20M*$16.70M*(m)$49.60M$82.10M-$12.80M
2021-06-30Reported$40.30M*$7.10M$33.20M*$397.50M10.14%*$67.00M*-$29.70M*$227.80M$48.90M$91.20M$2.60M
2021-03-31Reported$124.1M(m)(m)(m)36.18%$56.10M$5.10M$99.30M$52.50M$80.90M$15.50M
2020-12-31Reported$222.6M(m)(m)(m)38.18%(m)(m)(m)(m)(m)(m)
2020-09-30Reported$90.10M*$61.30M$28.80M*$385.20M23.39%*$45.70M*$105.20M*$149.00M$84.40M$75.50M$15.50M
2020-06-30Reported$154.60M*$126.00M$28.60M*$394.70M39.17%*$35.10M*$127.90M*$129.80M$47.90M$76.00M$28.00M
2020-03-31Reported$16.6M(m)(m)(m)8.62%$24.20M$57.80M$76.90M$42.70M$69.70M-$8.80M
2019-12-31Reported$44.4M(m)(m)(m)12.32%(m)(m)(m)(m)(m)(m)
2019-09-30Reported$98.40M*$70.70M$27.70M*$311.80M31.56%*$15.30M*-$3.10M*$108.00M$53.40M$65.00M$15.70M
2019-06-30Reported$21.50M*-$7.00M$28.50M*$243.20M8.84%*$14.10M*-$35.80M*$100.80M$63.90M$70.80M-$5.60M
2019-03-31Reported-$600,000.00(m)(m)(m)-0.31%$21.40M$104.80M$91.80M$46.10M$65.40M-$11.80M
2018-12-31Reported$10.4M(m)(m)(m)3.84%(m)(m)(m)(m)(m)(m)
2018-09-30Reported$33.70M*$21.30M$12.40M*$173.70M19.40%*$26.10M*$174.00M*$69.30M$37.00M$42.10M$600.00K
2018-06-30Reported$79.20M*$66.80M$12.40M*$220.20M35.97%*$13.60M*$34.60M*$85.30M$24.70M$39.50M$15.70M
2018-03-31Reported$2.8M(m)(m)(m)2.38%$11.60M-$1.00M$54.30M$29.10M$40.00M-$4.50M
2017-12-31Reported$55.39M(m)(m)(m)28.58%(m)(m)(m)(m)(m)(m)
2017-09-30Reported$57.57M*$47.77M$9.80M*$149.40M38.53%*$12.78M*$34.94M*$44.50M$22.66M$34.50M$12.76M
2017-06-30Reported$18.46M*$8.53M$9.93M*$100.80M18.31%*$9.30M*$54.00M*$34.62M$25.75M$31.87M$2.10M
2017-03-31Reported$25.08M(m)(m)(m)21.46%$20.30M$41.67M(m)$20.48M$35.15M$3.16M
2016-12-31Reported$50.78M(m)(m)(m)33.47%(m)(m)(m)(m)(m)(m)
2016-09-30Reported$45.86M*$35.48M$10.38M*(m)(m)$17.00M*$27.08M*(m)$27.19M$40.69M$13.16M
2016-06-30Reported$6.89M*-$2.04M$8.93M*(m)(m)$21.03M*(m)(m)$27.89M$35.92M-$1.27M
2016-03-31Reported$30M(m)(m)(m)29.13%$18.21M(m)(m)$26.09M$31.71M$7.96M
2015-12-31Reported$63.02M(m)(m)(m)39.44%(m)(m)(m)(m)(m)(m)
2015-09-30Reported$71.72M*$63.16M$8.56M*(m)(m)$13.95M*$104.76M*(m)$34.18M$25.80M$20.06M
2015-06-30Reported$30.22M*$21.45M$8.77M*(m)(m)$10.60M*$2.50M*(m)$40.94M$36.45M$5.50M
2015-03-31Reported-$19.78M(m)(m)(m)-31.08%$9.08M-$65.87M(m)$38.70M$34.49M-$8.27M
2014-12-31Reported$73.81M(m)(m)(m)72.14%(m)(m)(m)(m)(m)(m)
2014-09-30Reported$40.02M*$31.03M$8.99M*(m)(m)$5.22M*$78.92M*(m)$44.21M$30.29M$7.87M
2014-06-30Reported$16.32M*$7.86M$8.46M*(m)(m)$4.81M*$10.82M*(m)$37.40M$30.55M$2.46M
2014-03-31Reported-$18.62M(m)(m)(m)-34.56%$4.59M-$29.25M(m)$30.26M$30.09M-$8.21M
2013-12-31Reported$26.75M(m)(m)(m)27.27%(m)(m)(m)(m)(m)(m)
2013-09-30Reported$23.32M*$18.15M$5.17M*(m)(m)$20.30M*$60.13M*(m)$28.94M$21.95M$4.80M
2013-06-30Reported$18.92M*$14.71M$4.21M*(m)(m)$6.44M*$32.83M*(m)$30.28M$20.50M$4.38M
2013-03-31Reported-$9.19M(m)(m)(m)-21.32%$7.68M-$4.63M(m)$30.72M$20.03M-$4.52M
2012-12-31Reported$27.55M(m)(m)(m)29.12%(m)(m)(m)(m)(m)(m)
2012-09-30Reported$12.59M*$9.82M$2.77M*(m)(m)$10.02M*$46.48M*(m)$27.39M$19.16M$4.24M
2012-06-30Reported$11.19M*$8.65M$2.54M*(m)(m)$8.59M*$18.34M*(m)$30.64M$17.89M$4.04M
2012-03-31Reported-$10.17M(m)(m)(m)-20.20%$22.33M$13.84M(m)$26.25M$19.49M-$3.64M
2011-12-31Reported$48.42M(m)(m)(m)44.85%(m)(m)(m)(m)(m)(m)
2011-09-30Reported$3.82M*$1.41M$2.41M*(m)(m)$17.36M*$4.66M*(m)$29.22M$17.43M$1.60M
2011-06-30Reported$22.49M*$20.21M$2.28M*(m)(m)$8.36M*-$6.68M*(m)$31.48M$20.38M$7.66M
2011-03-31Reported-$33.27M(m)(m)(m)-179.52%$8.43M-$22.72M(m)$34.76M$18.21M-$12.30M
2010-12-31Reported$36.93M(m)(m)(m)35.77%(m)(m)(m)(m)(m)(m)
2010-09-30Reported$21.98M*$20.61M$1.37M*(m)(m)$5.41M*$54.17M*(m)$21.16M$20.69M$7.70M
2010-06-30Reported(m)$14.81M(m)(m)(m)(m)(m)(m)$18.60M$17.65M$5.76M

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported$195.9M(m)(m)(m)26.37%$13.80M$170.60M$326.20M$53.20M$186.10M$30.20M
2024-12-31Reported$100,000.00(m)(m)(m)0.01%$22.90M$58.70M$681.30M$70.70M$308.00M$47.70M
2023-12-31Reported-$601.3M(m)(m)(m)-57.30%$51.60M-$206.30M$705.40M$111.40M$368.40M$29.30M
2023-09-30Rolling(m)-$737.90M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2023-06-30Rolling(m)-$541.10M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2023-03-31Rolling(m)-$324.50M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-12-31Reported-$26.7M(m)(m)(m)-2.39%$115.80M-$34.10M$693.10M$188.30M$339.50M-$7.40M
2022-12-31Rolling(m)-$170.00M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-09-30Rolling(m)$172.10M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-06-30Rolling(m)$172.70M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2022-03-31Rolling(m)$256.10M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-12-31Reported$465.2M(m)(m)(m)26.23%$224.10M$320.20M$748.10M$235.20M$348.70M$83.70M
2021-12-31Rolling(m)$341.40M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-09-30Rolling(m)$312.70M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2021-06-30Rolling(m)$418.70M*(m)$1.71B*(m)(m)(m)(m)(m)(m)(m)
2021-03-31Rolling(m)$537.60M*(m)$1.71B*(m)(m)(m)(m)(m)(m)(m)
2020-12-31Reported$483.9M(m)(m)(m)31.11%$141.90M$536.90M$537.00M$237.90M$304.10M$106.10M
2020-12-31Rolling(m)$433.80M*(m)$1.56B*(m)(m)(m)(m)(m)(m)(m)
2020-09-30Rolling(m)$253.50M*(m)$1.33B*(m)(m)(m)(m)(m)(m)(m)
2020-06-30Rolling(m)$262.90M*(m)$1.26B*(m)(m)(m)(m)(m)(m)(m)
2020-03-31Rolling(m)$129.90M*(m)$1.11B*(m)(m)(m)(m)(m)(m)(m)
2019-12-31Reported$163.6M(m)(m)(m)14.79%$86.90M$188.00M$433.50M$226.20M$273.50M$22.90M
2019-12-31Rolling(m)$114.10M*(m)$1.11B*(m)(m)(m)(m)(m)(m)(m)
2018-12-31Reported$126.1M(m)(m)(m)16.12%$72.10M$41.80M$322.30M$142.80M$202.50M$18.80M
2017-12-31Reported$156.5M(m)(m)(m)27.90%$54.80M$208.10M$187.70M$97.40M$142.90M$36.00M
2016-12-31Reported$133.52M(m)(m)(m)27.32%$76.20M$54.60M$126.30M$106.90M$143.10M$36.70M
2016-09-30Rolling(m)$104.48M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2016-06-30Rolling(m)$132.17M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2016-03-31Rolling(m)$155.66M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2015-12-31Reported$165.25M(m)(m)(m)33.77%$44.81M$42.52M(m)$119.19M$121.14M$44.30M
2015-12-31Rolling(m)$106.19M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2015-09-30Rolling(m)$100.92M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2015-06-30Rolling(m)$68.79M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2015-03-31Rolling(m)$55.20M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2014-12-31Reported$111.53M(m)(m)(m)27.57%$30.67M$112.32M(m)$104.72M$108.59M$29.93M
2014-12-31Rolling(m)$58.06M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2014-09-30Rolling(m)$36.73M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2014-06-30Rolling(m)$23.84M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2014-03-31Rolling(m)$30.69M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2013-12-31Reported$59.81M(m)(m)(m)19.12%$42.02M$96.97M(m)$119.93M$87.88M$13.11M
2013-12-31Rolling(m)$42.80M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2013-09-30Rolling(m)$43.54M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2013-06-30Rolling(m)$35.21M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2013-03-31Rolling(m)$29.16M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2012-12-31Reported$41.16M(m)(m)(m)14.60%$53.84M$39.64M(m)$120.23M$76.02M$13.92M
2012-12-31Rolling(m)$29.97M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2012-09-30Rolling(m)$51.92M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2012-06-30Rolling(m)$43.51M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2012-03-31Rolling(m)$55.07M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2011-12-31Reported$41.45M(m)(m)(m)15.16%$54.03M$12.19M(m)$124.83M$74.28M$15.83M
2011-12-31Rolling(m)$32.10M*(m)(m)(m)(m)(m)(m)(m)(m)(m)
2010-12-31Reported$79.55M(m)(m)(m)27.80%$22.10M$98.02M(m)$89.30M$76.20M$26.18M
2009-12-31Reported$45.15M(m)(m)(m)19.23%$33.29M$29.87M(m)$74.59M$73.79M$14.97M

Similar stocks

Stock NameCountryMarket CapPE Ratio
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Rezolute, Inc. (RZLT)United States$0.382B-6.45